Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell 
xenograft tumor models

Zhao,Ming; Ma,Qian; Xu,Jinhui; Fu,Shaozhi; Chen,Lanlan; Wang,Biqiong; Wu,Jingbo; Yang,Linglin

doi:10.3892/ol.2015.3281

August-2015 Volume 10 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2015 Volume 10 Issue 2

Full Size Image

Article Open Access

Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models

Authors:
- Ming Zhao
- Qian Ma
- Jinhui Xu
- Shaozhi Fu
- Lanlan Chen
- Biqiong Wang
- Jingbo Wu
- Linglin Yang
View Affiliations / Copyright

Affiliations: Department of Oncology, Affliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China

Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 768-772
|
Published online on: May 27, 2015

https://doi.org/10.3892/ol.2015.3281
Expand metrics +

Abstract

Radiotherapy is an important treatment method for cervical cancer, but the efficacy requires improvement. Therefore, novel methods of treatment are required. Previous data have demonstrated that the CXC chemokine ligand 10 (CXCL10) inhibits angiogenesis, induces apoptosis and causes avoidance of the S phase of the cell cycle in cervical cancer cells. The aim of the present study was to evaluate the anti‑tumor effect of radiotherapy combined with CXCL10 gene therapy. Mouse models of cervical carcinoma were created by inoculation with HeLa cells, and were treated by combining intravenously administered plasmid‑encoding CXCL10, administered 5 times (days 12, 15, 18, 21 and 24 following inoculation), with direct radiation (20 Gy/5 fractions) administered on 5 consecutive days (~day 27 after inoculation). The vessel density and tumor cell proliferation were observed by immunostaining, and apoptosis was determined using a TUNEL assay. The results revealed a significant increase in the inhibition of tumor growth, reduced vessel density, decreased cell proliferation and increased apoptosis in the tumor cells of the combination therapy group. Overall, these findings resulted in the conclusion that CXCL10 gene therapy in combination with radiotherapy is a novel effective therapeutic strategy for cervical cancer.

View Figures

View References

1	Schiffman M and Castle PE: The promise of global cervical cancer prevention. N Engl J Med. 353:2101–2104. 2005. View Article : Google Scholar : PubMed/NCBI
2	Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J and Shah K: Benefts and costs of using HPV testing to screen for cervical cancer. JAMA. 287:2372–2381. 2002. View Article : Google Scholar : PubMed/NCBI
3	Small W Jr, Mell LK, Anderson P, et al: Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 71:428–434. 2008. View Article : Google Scholar : PubMed/NCBI
4	Grigsby PW: Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer. Radiat Med. 23:327–330. 2005.PubMed/NCBI
5	Klopp AH and Eifel PJ: Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep. 13:77–85. 2011. View Article : Google Scholar : PubMed/NCBI
6	Tanderup K, Georg D, Pötter R, Kirisits C, Grau C and Lindegaard JC: Adaptive management of cervical cancer radiotherapy. Semin Radiat Oncol. 20:121–129. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bromley SK, Mempel TR and Luster AD: Orchestrating the orchestrators: Chemokines in control of T cell traffic. Nat Immunol. 9:970–980. 2008. View Article : Google Scholar : PubMed/NCBI
8	Luster AD, Unkeless JC and Ravetch JV: Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 315:672–676. 1985. View Article : Google Scholar : PubMed/NCBI
9	Campanella GS, Colvin RA and Luster AD: CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One. 5:e127002010. View Article : Google Scholar : PubMed/NCBI
10	Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, et al: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 184:981–992. 1996. View Article : Google Scholar : PubMed/NCBI
11	Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA and Lode HN: IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol. 166:6944–6951. 2001. View Article : Google Scholar : PubMed/NCBI
12	Feldman AL, Friedl J, Lans TE, et al: Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer. 99:149–159. 2002. View Article : Google Scholar : PubMed/NCBI
13	Yang LL, Chen P, Luo S, Li J, Liu K, Hu HZ and Wei YQ: CXC-chemokine-ligand-10 gene therapy efﬁciently inhibits the growth of cervical carcinoma on the basis of its anti-angiogenic and antiviral activity. Biotechnol Appl Biochem. 53:209–216. 2009.PubMed/NCBI
14	Yang LL, Wang BQ, Chen LL, Luo HQ and Wu JB: CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution. Onclogy Lett. 3:383–386. 2012.
15	Xiao F, Wei Y, Yang L, et al: A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 9:1207–1213. 2002. View Article : Google Scholar : PubMed/NCBI
16	Somasundaram K and El-Deiry WS: Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. 14:1047–57. 1997. View Article : Google Scholar : PubMed/NCBI
17	Li G, Tian L, Hou JM, et al: Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin Cancer Res. 11:4217–4224. 2005. View Article : Google Scholar : PubMed/NCBI
18	Han GD, Suzuki K, Koike H, et al: IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. J Am Soc Nephrol. 17:442–453. 2006. View Article : Google Scholar : PubMed/NCBI
19	Mazumder S, Plesca D and Almasan A: A jekyll and hyde role of cyclin E in the genotoxic stress response: switching from cell cycle control to apoptosis regulation. Cell Cycle. 6:1437–1442. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kawauchi S, Yamamoto Y, Uchida K, Chochi Y, Kondo T, Oga A and Sasaki K: Signifcance of cyclin E and p27 expression in malignant ovarian germ cell tumors: Correlation with the cell proliferation activity and clinicopathologic features. Oncol Rep. 16:1029–1033. 2006.PubMed/NCBI
21	Frosina G: DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res. 7:989–999. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI